A new enabling act provides a "once-in-a-generation" opportunity to reform Italy's pharmaceutical legislation, with a focus on tackling regional access delays and preparing for high-cost gene therapies.
The Italian Medicines Agency's latest expenditure report reveals a significant overspend on medicines for the first third of the year, driven primarily by costs for new cancer drugs and cardiovascular therapies.
Italy’s Agency for Medicines (AIFA) has approved updated rules for its organisation and staffing, aiming to streamline medicine access and ensure financial sustainability and patient safety
